These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 26119939)

  • 1. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
    Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
    Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
    Patil A; Manzano M; Gottwein E
    Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.
    Tolani B; Gopalakrishnan R; Punj V; Matta H; Chaudhary PM
    Oncogene; 2014 May; 33(22):2928-37. PubMed ID: 23792448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
    Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
    Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma.
    Siu KT; Ramachandran J; Yee AJ; Eda H; Santo L; Panaroni C; Mertz JA; Sims Iii RJ; Cooper MR; Raje N
    Leukemia; 2017 Aug; 31(8):1760-1769. PubMed ID: 27890933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma.
    Zhou F; Shimoda M; Olney L; Lyu Y; Tran K; Jiang G; Nakano K; Davis RR; Tepper CG; Maverakis E; Campbell M; Li Y; Dandekar S; Izumiya Y
    Mol Cancer Ther; 2017 Nov; 16(11):2627-2638. PubMed ID: 28847988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance.
    Davis LN; Walker ZJ; Reiman LT; Parzych SE; Stevens BM; Jordan CT; Forsberg PA; Sherbenou DW
    Clin Cancer Res; 2024 Jul; 30(14):3023-3035. PubMed ID: 38723281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
    Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
    Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kaposi's Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma.
    Manzano M; Günther T; Ju H; Nicholas J; Bartom ET; Grundhoff A; Gottwein E
    mBio; 2020 Aug; 11(4):. PubMed ID: 32843547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
    Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
    Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
    Lu J; Qian Y; Altieri M; Dong H; Wang J; Raina K; Hines J; Winkler JD; Crew AP; Coleman K; Crews CM
    Chem Biol; 2015 Jun; 22(6):755-63. PubMed ID: 26051217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.
    Bhatt S; Ashlock BM; Toomey NL; Diaz LA; Mesri EA; Lossos IS; Ramos JC
    J Clin Invest; 2013 Jun; 123(6):2616-28. PubMed ID: 23635777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.
    Fionda C; Abruzzese MP; Zingoni A; Cecere F; Vulpis E; Peruzzi G; Soriani A; Molfetta R; Paolini R; Ricciardi MR; Petrucci MT; Santoni A; Cippitelli M
    Oncotarget; 2015 Sep; 6(27):23609-30. PubMed ID: 26269456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
    Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
    Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Narciclasine, an isocarbostyril alkaloid, has preferential activity against primary effusion lymphoma.
    Gopalakrishnan R; Matta H; Choi S; Chaudhary PM
    Sci Rep; 2020 Mar; 10(1):5712. PubMed ID: 32235878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of primary effusion lymphoma engraftment in SCID mice by morpholino oligomers against early lytic genes of Kaposi's sarcoma-associated herpesvirus.
    Zhang YJ; Patel D; Nan Y; Fan S
    Antivir Ther; 2011; 16(5):657-66. PubMed ID: 21817187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma.
    Sarosiek KA; Cavallin LE; Bhatt S; Toomey NL; Natkunam Y; Blasini W; Gentles AJ; Ramos JC; Mesri EA; Lossos IS
    Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13069-74. PubMed ID: 20615981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors.
    Wang C; Zhang L; Ke L; Ding W; Jiang S; Li D; Narita Y; Hou I; Liang J; Li S; Xiao H; Gottwein E; Kaye KM; Teng M; Zhao B
    Nat Commun; 2020 Dec; 11(1):6318. PubMed ID: 33298918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cucurbitacin B induces apoptosis of primary effusion lymphoma via disruption of cytoskeletal organization.
    Ueno M; Kariya R; Sittithumcharee G; Okada S
    Phytomedicine; 2021 May; 85():153545. PubMed ID: 33799222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
    Zheng J; Sha Y; Roof L; Foreman O; Lazarchick J; Venkta JK; Kozlowski C; Gasparetto C; Chao N; Ebens A; Hu J; Kang Y
    Cancer Lett; 2019 Jan; 440-441():1-10. PubMed ID: 30312729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.